Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke
Top Cited Papers
- 16 February 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 96 (7), e1012-e1023
- https://doi.org/10.1212/wnl.0000000000011440
Abstract
Objective To test whether autologous modified mesenchymal stem cells (MSCs) improve recovery in patients with chronic major stroke. Methods In this prospective, open-label, randomized controlled trial with blinded outcome evaluation, patients with severe middle cerebral artery territory infarct within 90 days of symptom onset were assigned, in a 2:1 ratio, to receive preconditioned autologous MSC injections (MSC group) or standard treatment alone (control group). The primary outcome was the score on the modified Rankin Scale (mRS) at 3 months. The secondary outcome was to further demonstrate motor recovery. Results A total of 39 and 15 patients were included in the MSC and control groups, respectively, for the final intention-to-treat analysis. Mean age of patients was 68 (range 28–83) years, and mean interval between stroke onset to randomization was 20.2 (range 5–89) days. Baseline characteristics were not different between groups. There was no significant difference between the groups in the mRS score shift at 3 months (p = 0.732). However, secondary analyses showed significant improvements in lower extremity motor function in the MSC group compared to the control group (change in the leg score of the Motricity Index, p = 0.023), which was notable among patients with low predicted recovery potential. There were no serious treatment-related adverse events. Conclusions IV application of preconditioned, autologous MSCs with autologous serum was feasible and safe in patients with chronic major stroke. MSC treatment was not associated with improvements in the 3-month mRS score, but we did observe leg motor improvement in detailed functional analyses. Classification of Evidence This study provides Class III evidence that autologous MSCs do not improve 90-day outcomes in patients with chronic stroke. ClinicalTrials.gov Identifier NCT01716481.This publication has 38 references indexed in Scilit:
- Cell TherapiesStroke, 2013
- Estimating the Minimal Clinically Important Difference of an Upper Extremity Recovery Measure in Subacute Stroke PatientsTopics in Stroke Rehabilitation, 2011
- Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in strokeBrain, 2011
- Comparison of Bone Marrow Stromal Cells Derived From Stroke and Normal Rats for Stroke TreatmentStroke, 2010
- Treatment effects for which shift or binary analyses are advantageous in acute stroke trialsNeurology, 2009
- Clinical Trials of Stroke TherapyStroke, 2009
- Autologous mesenchymal stem cell transplantation in stroke patientsAnnals of Neurology, 2005
- Central Nervous System Entry of Peripherally Injected Umbilical Cord Blood Cells Is Not Required for Neuroprotection in StrokeStroke, 2004
- Measuring arm impairment and disability after strokeInternational Disability Studies, 1989
- Motor Evaluation in Vascular HemiplegiaEuropean Neurology, 1980